This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
A brave new Europe with the introduction of the EU Clinical Trials Directive: Impact upon the pharma industry and academic research with special emphasis on…
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Intellectual property: The driving force for growth and funding
Go to paperABSTRACT: For most ‘bio-entrepreneurs’ the science is the easy part — leveragin…
Intellectual property: The driving force for growth and funding Read Post »
Made available by the elective open access option at the Journal of Commercial Biotechnology, this paper is free to view without subscription: The
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Fostering the process of adoption of personalised medicine: A matter of communication or a matter of cost?
Go to paperABSTRACT: Pharmacogenetics, along with…
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post?
Biotechnology in Countries Starting with "I" – Part 4: Ireland Read Post »
This guest post is from the BiotechBlog Intern, Fintan Burke. Fintan is a student at the School of Biotechnology at Dublin
Crowdsourcing in the Biotech world: Innovation and outreach to a wider public Read Post »
In the last weeks, India has seen serious setbacks to its life sciences industry. The NIH recently announced that they
I am off to Taiwan for the “Asian Food and Agribusiness Conference 2013” and then a brief stopover in Korea.
Five years ago I built a biotechnology innovation index and I have been using it since tracking global biotechnology innovation
The 1980 Supreme Court decision in Diamond v. Chakrabarty established the patentability of human modifications to bacteria, and arguably laid
Biotechnology patenting pioneer muses on Myriad ruling Read Post »
Get new actionable insights and updates from BiotechBlog
